Venetoclax + Inotuzumab: Changing the Game in Relapsed ALLL | Marlise Luskin, MD

Can MRD Guide Better CLL Treatment With Sonrotoclax? | Marc Hoffmann, MD

Less Invasive AML & MDS Monitoring: Blood Tests & Machine Learning | Lisa Pleyer, MD

Real‑World Results for Menin Inhibitors in Hard‑to‑Treat AML | Kuo-Kai Chin, MD

MECOM Rearrangements in AML: What Patients Need to Know | Jesus Gonzales Lugo, MD

Can Nadir Bone Marrow Predict AML Outcomes? New Trial Data | Douglas Tremblay, MD

New SEQUOIA Trial Results Shake Up First‑Line CLL Care! | Amit Agarwal, MD, PhD

Non-Covalent vs Covalent BTK Inhibitors: What’s Best of Patients | Jennifer Woyach, MD

Is the Blexi‑Ven Combo Safe and Effective? | Jenny O'Nions, MD

Is Time-Limited Therapy the Future for CLL? | Romain Guieze, MD

Is Rocbrutinib a New Option for CLL Patients? Phase 1 Trial Updates | Jennifer Woyach, MD

Is 1-Year Therapy Just as Effective as Multiple Years? | Othman Al-Sawaf, MD

Mosunetuzumab: A Potential Option for Frail DLBCL Patients | Jeff Sharman, MD

Hypomethylating agent for newly diagnosed TP53-mutant AML | Talher Badar, MBBS, MD

Ibrutinib + Venetoclax (I+V) for CLL: Findings from CAPTIVATE & GLOW | Paolo Ghia, MD, PhD

Optimal 2nd-Line Treatment for CLL? GAIA/CLL13 Findings | Carsten Niemann, MD

Improving Outcomes in FLT3-mutant AML: Crenolanib + Chemo | Thomas Cluzeau, MD, PhD

BETA - What is some of the most promising research being done to treat chronic lymphocytic leukemia?